"All patients being treated with CHANTIX should be observed for neuropsychiatric symptoms including changes in behavior, hostility, agitation, depressed mood, and suicide-related events, including ideation, behavior, and attempted suicide. These symptoms, as well as worsening of pre-existing psychiatric illness and completed suicide, have been reported in some patients attempting to quit smoking while taking CHANTIX in the postmarketing experience. ... Advise patients and caregivers that the patient should stop taking CHANTIX and contact a healthcare provider immediately if agitation, hostility, depressed mood, or changes in behavior or thinking that are not typical for the patient are observed, or if the patient develops suicidal ideation or suicidal behavior."

The reason for the failure of these researchers to disclose their past relationships with the tobacco industry is not entirely clear, but may revolve around their interpretation of the conflict of interest disclosure form's requirements. In section 3 of the form, authors of articles are asked to disclose any financial relationships with industry that occurred within the past three years. However, neither of the two co-authors has received money from any tobacco companies since 2010.

Price

Christopher Snowdon reported the details of the story back in February. He wrote:

LAST：eGo CE4 clearomizer blister pack electronic cigarette |NEXT：New arrived ecig RDA/RBA atomizer fogger v4 mech mod atomizer wholesale exgo w3